Last reviewed · How we verify

Azacitidine Injection [Vidaza]

Grupo Cooperativo de Estudio y Tratamiento de las Leucemias Agudas y Mielodisplasias · Phase 2 active Small molecule

Azacitidine Injection [Vidaza] is a Hypomethylating agent Small molecule drug developed by Grupo Cooperativo de Estudio y Tratamiento de las Leucemias Agudas y Mielodisplasias. It is currently in Phase 2 development for Acute myeloid leukemia, Mylodysplastic syndromes.

Inhibits DNA methyltransferase

Inhibits DNA methyltransferase Used for Acute myeloid leukemia, Mylodysplastic syndromes.

At a glance

Generic nameAzacitidine Injection [Vidaza]
SponsorGrupo Cooperativo de Estudio y Tratamiento de las Leucemias Agudas y Mielodisplasias
Drug classHypomethylating agent
TargetDNA methyltransferase
ModalitySmall molecule
Therapeutic areaOncology
PhasePhase 2

Mechanism of action

Azacitidine is a hypomethylating agent that works by inhibiting DNA methyltransferase, leading to a decrease in DNA methylation and an increase in gene expression.

Approved indications

Common side effects

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

Frequently asked questions about Azacitidine Injection [Vidaza]

What is Azacitidine Injection [Vidaza]?

Azacitidine Injection [Vidaza] is a Hypomethylating agent drug developed by Grupo Cooperativo de Estudio y Tratamiento de las Leucemias Agudas y Mielodisplasias, indicated for Acute myeloid leukemia, Mylodysplastic syndromes.

How does Azacitidine Injection [Vidaza] work?

Inhibits DNA methyltransferase

What is Azacitidine Injection [Vidaza] used for?

Azacitidine Injection [Vidaza] is indicated for Acute myeloid leukemia, Mylodysplastic syndromes.

Who makes Azacitidine Injection [Vidaza]?

Azacitidine Injection [Vidaza] is developed by Grupo Cooperativo de Estudio y Tratamiento de las Leucemias Agudas y Mielodisplasias (see full Grupo Cooperativo de Estudio y Tratamiento de las Leucemias Agudas y Mielodisplasias pipeline at /company/grupo-cooperativo-de-estudio-y-tratamiento-de-las-leucemias-agudas-y-mielodispla).

What drug class is Azacitidine Injection [Vidaza] in?

Azacitidine Injection [Vidaza] belongs to the Hypomethylating agent class. See all Hypomethylating agent drugs at /class/hypomethylating-agent.

What development phase is Azacitidine Injection [Vidaza] in?

Azacitidine Injection [Vidaza] is in Phase 2.

What are the side effects of Azacitidine Injection [Vidaza]?

Common side effects of Azacitidine Injection [Vidaza] include Fatigue, Nausea, Diarrhea, Pyrexia, Cough.

What does Azacitidine Injection [Vidaza] target?

Azacitidine Injection [Vidaza] targets DNA methyltransferase and is a Hypomethylating agent.

Related